Skip to content

Study · Observational study · n = 14 · 2018

11 results

Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism.

Winer KK, Kelly A, Johns A, Zhang B, Dowdy K, Kim L, Reynolds JC, Albert PS, Cutler GB Jr

The Journal of pediatrics1 Dec 2018Cited by 39 (Europe PMC)

PMID30470382 (opens in a new tab)PMCIDPMC6298875 (opens in a new tab)DOI10.1016/j.jpeds.2018.08.010 (opens in a new tab)PepBankPUB-30470382
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In children with hypoparathyroidism receiving PTH 1‑34, mean height velocity remained normal throughout observation.

    In plain wordsIn children receiving PTH 1‑34, growth speed remained normal.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableHeight velocity
    Study

    n = 14

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Source sentences

    Summary
    Mean height velocity and lumbar spine, whole body, and femoral neck bone accretion velocities were normal throughout the study.
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  2. 02HumanObservational studyEfficacy outcome

    In children with hypoparathyroidism receiving PTH 1‑34, lumbar spine bone accretion velocity remained normal.

    In plain wordsIn children receiving PTH 1‑34, lower spine bone growth remained normal.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableLumbar spine bone accretion velocity
    Study

    n = 14

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Source sentences

    Summary
    Mean height velocity and lumbar spine, whole body, and femoral neck bone accretion velocities were normal throughout the study.
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  3. 03HumanObservational studyEfficacy outcome

    In children with hypoparathyroidism receiving PTH 1‑34, whole body bone accretion velocity remained normal.

    In plain wordsIn children receiving PTH 1‑34, whole body bone growth remained normal.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableWhole body bone accretion velocity
    Study

    n = 14

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Source sentences

    Summary
    Mean height velocity and lumbar spine, whole body, and femoral neck bone accretion velocities were normal throughout the study.
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  4. 04HumanObservational studyEfficacy outcome

    In children with hypoparathyroidism receiving PTH 1‑34, femoral neck bone accretion velocity remained normal.

    In plain wordsIn children receiving PTH 1‑34, femoral neck bone growth remained normal.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableFemoral neck bone accretion velocity
    Study

    n = 14

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Source sentences

    Summary
    Mean height velocity and lumbar spine, whole body, and femoral neck bone accretion velocities were normal throughout the study.
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  5. 05HumanObservational studyEfficacy outcome

    In children receiving PTH 1‑34, distal radius bone accrual velocity was lower than normal during the first 2 years.

    In plain wordsIn children receiving PTH 1‑34, forearm bone growth was lower than in normal children during the first 2 years.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseDistal radius bone accrual velocity
    Study

    n = 14

    Comparator
    Normal children
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Source sentences

    Summary
    In the first 2 years, distal one-third radius bone accrual velocity was reduced compared with normal children (P < .003).
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  6. 06HumanObservational studyEfficacy outcome

    In children receiving PTH 1‑34, mean serum calcium was 2.05 mmol/L.

    In plain wordsIn children receiving PTH 1‑34, average blood calcium was 2.05 mmol/L.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableSerum calcium
    Study

    n = 14

    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Measurements

    Mean serum calcium
    2.05 mmol/L
    during PTH 1-34 therapy

    Source sentences

    Summary
    Mean serum and 24-hour urine calcium levels were 2.05 ± 0.11 mmol/L (N: 2.05-2.5 mmol/L) and 6.93 ± 1.3 mmol/24 hour (N: 1.25-7.5 mmol/24 hour), respectively-with fewer high urine calcium levels vs baseline during calcitriol and calcium treatment (P < .001).
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  7. 07HumanObservational studyEfficacy outcome

    In children receiving PTH 1‑34, mean urine calcium was 6.93 mmol/24 hour.

    In plain wordsIn children receiving PTH 1‑34, average urine calcium was 6.93 mmol/24 hour.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableUrine calcium
    Study

    n = 14

    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Measurements

    Mean urine calcium
    6.93 mmol/24 hour
    during PTH 1-34 therapy

    Source sentences

    Summary
    Mean serum and 24-hour urine calcium levels were 2.05 ± 0.11 mmol/L (N: 2.05-2.5 mmol/L) and 6.93 ± 1.3 mmol/24 hour (N: 1.25-7.5 mmol/24 hour), respectively-with fewer high urine calcium levels vs baseline during calcitriol and calcium treatment (P < .001).
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  8. 08HumanObservational studyEfficacy outcome

    In children with hypoparathyroidism, high urine calcium levels were less frequent during PTH 1‑34 than during baseline calcitriol and calcium treatment.

    In plain wordsIn children, high urine calcium was less frequent during PTH 1‑34 than during baseline calcitriol and calcium treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseHigh urine calcium frequency
    Study

    n = 14

    Comparator
    Baseline during calcitriol and calcium treatment
    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Source sentences

    Summary
    Mean serum and 24-hour urine calcium levels were 2.05 ± 0.11 mmol/L (N: 2.05-2.5 mmol/L) and 6.93 ± 1.3 mmol/24 hour (N: 1.25-7.5 mmol/24 hour), respectively-with fewer high urine calcium levels vs baseline during calcitriol and calcium treatment (P < .001).
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  9. 09HumanObservational studySafety outcome

    In children receiving PTH 1‑34, nephrocalcinosis progressed in 5 of 12 with repeated renal imaging.

    In plain wordsIn children receiving PTH 1‑34, kidney calcium deposits progressed in 5 of 12 with repeated imaging.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableNephrocalcinosis progression
    Study

    n = 12

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Measurements

    Subjects with nephrocalcinosis progression
    5 subjects
    of 12 with repeated renal imaging

    Source sentences

    Summary
    Nephrocalcinosis progressed in 5 of 12 subjects who had repeated renal imaging although renal function remained normal.
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).
  10. 10HumanObservational studyEfficacy outcome

    In children receiving PTH 1‑34, renal function remained normal despite nephrocalcinosis progression.

    In plain wordsIn children receiving PTH 1‑34, kidney function remained normal despite progression of calcium deposits.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableRenal function
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.75 ± 0.15 µg/kg/day · subcutaneous · 6.9 ± 3.1 yearsAs given in this study (human).

    Source sentences

    Summary
    Nephrocalcinosis progressed in 5 of 12 subjects who had repeated renal imaging although renal function remained normal.
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 11HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In children receiving PTH 1‑34, alkaline phosphatase correlated with dose and remained normal.

    In plain wordsIn children receiving PTH 1‑34, alkaline phosphatase was linked to dose and remained normal.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableAlkaline phosphatase
    Study

    n = 14

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Mean alkaline phosphatase
    235.3 U/L
    during PTH 1-34 therapy

    Source sentences

    Summary
    Serum alkaline phosphatase correlated with PTH 1-34 dose (P < .006) and remained normal (235.3 ± 104.8 [SD] U/L, N: 51-332 U/L).
    2 context sentences
    Summary · context
    Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
    Summary · context
    Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.